Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Closes eGene Buy, Expects It to Contribute As Much As $9M in '08

NEW YORK (GenomeWeb News) — Qiagen said today that it has closed its $34 million acquisition of eGene, and said it expects the company to contribute strong revenue growth by next year.
Specifically, the company said it expects the acquisition to contribute $2 million in the second half of 2007 and between $7 million and $9 million for full year 2008.
The acquisition, originally announced April 12, gives Qiagen’s North American Holdings subsidiary eGene’s multi-channel sample-separation and -analysis technology, its HDA GT12 genetic analyzer, as well as a software-analysis package and consumable cartridges used by molecular diagnostics and research markets.
The total purchase price for Irvine, Calif.-based eGene includes $15.5 million in cash and one million common Qiagen shares priced at $17 apiece. Qiagen also absorbed around $1.5 million in liabilities.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.